Avid Bioservices Inc (CDMO): Listed below are the dates where volume...

Reply Private New

Replies (2) Next 10 Prev Next

Send PM Follow Ignore

Followers	32
Posts	5818
Boards Moderated	0
Alias Born	05/23/2006

jakedogman1

Re: None

Monday, 02/20/2017 4:21:27 PM

Monday, February 20, 2017 4:21:27 PM

Listed below are the dates where volume exceeded Friday’s volume. Each occurrence had a PR… either very good or very bad news…. What is odd about recent volume is no news…

2/17/17 26 mil no news

3/5/14 3/6/14 36 mil and 32 mil

http://ir.peregrineinc.com/releases.cfm?Year=2014&ReleasesType=&PageNum=2

Peregrine Pharmaceuticals PS-Targeting Immunotherapy Platform to Be Highlighted in Three Data Presentations at Keystone Symposia Conferences

2/13/13 31 mil

http://ir.peregrineinc.com/releases.cfm?Year=2013&ReleasesType=&PageNum=2

Peregrine Pharmaceuticals Announces Results From Phase II Clinical Trial of Bavituximab in Stage IV Pancreatic Cancer

1/7/13 62 mil and 32 mil

http://ir.peregrineinc.com/releases.cfm?Year=2013&ReleasesType=&PageNum=2

Peregrine Pharmaceuticals Provides Update on the Internal Review of Its Phase II Second-Line Non-Small Cell Lung Cancer Trial

9/24/12 close to 200 mil over 4 days
You know this story…

9/7/12 29 mil

http://ir.peregrineinc.com/releases.cfm?ReleasesType=&Year=2012

Interim Data From Peregrine's Phase II Trial in Second-Line Non-Small Cell Lung Cancer Demonstrate Doubling of Median Overall Survival in Bavituximab-Containing Arms